Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics. The company aims to bring simple, elegant, and cost-effective solutions to common problems facing research and development programs.
Vizgen is a privately held biotech company developing the next generation of spatially resolved, single-cell transcriptomics technology and toolbox. The company's patented MERFISH technology enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and detection efficiency at subcellular resolution.
Transition Bio provides condensate technology for drug discovery and diagnostics. The company focuses on the discovery, analysis, and modulation of biological condensates, propelled by a differentiated technological capability that generates expansive drug development opportunities in a hypothesis-free manner.
Ansa Biotechnologies is manufactured via a chemical method that has remained essentially unchanged for 35 years and has approached a plateau. Ansa Biotechnologies is developing a novel DNA synthesis technology based on enzymes that will be more fast, accurate, and clean than existing methods. The technique promises to dramatically accelerate innovation in biological research and engineering.
Sherlock Biosciences is a biotechnology company based in Cambridge, Massachusetts, focused on developing molecular diagnostic solutions. Incorporated in 2018, the company utilizes cutting-edge engineering biology tools, including CRISPR and synthetic biology, to create innovative diagnostic platforms. Its primary products include SHERLOCK, a CRISPR-based method for detecting and quantifying specific genetic sequences, and INSPECTR, a synthetic biology-based diagnostics platform. These technologies aim to provide rapid, accurate, and affordable results across various applications, including precision oncology, infection identification, food safety, at-home testing, and disease detection. By leveraging these advanced tools, Sherlock Biosciences addresses the need for effective diagnostics in both high and low-resource settings.
Scipher Medicine develops a healthcare platform designed to determine which drug will work best for each patient. The company is committed to transforming the way providers prescribe drugs, as well as the way manufacturers, develop new drugs. They are building a molecular map of all protein interactions that identifies genomic signatures and links those to disease and predictive treatment outcomes. Using a simple blood sample to analyze RNA, Scipher Medicine can predict if a patient is likely to respond to a targeted therapy before therapy is prescribed. This insight allows patients to start the most effective therapy from day one. For its first commercial product, they have developed PrismRA®, a first-of-its-kind blood test that can predict which patients with rheumatoid arthritis are less likely to respond to TNFi therapies such as Humira® and Enbrel® so that such patients can go on alternative approved drugs. Scipher Medicine is building the future of patient treatment. Most patients who are prescribed blockbuster therapies today don't respond to treatment, costing the healthcare industry billions in wasted drugs while patients continue to suffer. Scipher's platform identifies which drug will work based on the patient's fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A routine blood test predicts which drug he/she will respond to, with our first product focusing on rheumatoid arthritis, ensuring that the most optimal treatment is prescribed from day one. The molecular data generated by our tests are then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to any existing therapy.
Walking Fish Therapeutics is focused on creating cell-based therapeutics that utilize the unique capabilities of B cells to activate the immune system for cancer treatment. The company is developing a platform that aims to function as in vivo protein factories, producing replacement proteins for deficiency diseases and engineered antibodies. By harnessing the power of locally acting proteins, Walking Fish Therapeutics seeks to address serious health conditions across oncology, regenerative medicine, and autoimmune diseases, ultimately enabling healthcare providers to concentrate on innovative therapeutic approaches in these fields.
1859 is a biotechnology company focusing on the discovery and development of next-generation therapeutics. The company was founded in 2019 and is headquartered in San Diego, California.
64x Bio builds a platform that increases the speed and scale of mammalian cell line discovery. The company uses a throughput discovery and screening platform and an integrated computational design loop, they develop new ways of generating highly optimized and otherwise unattainable cell lines for the manufacturing of viral vectors, with a specific focus on those used for cell and gene therapies.
SimBioSys is developing a Computational Microscope that integrates state-of-the-art simulation techniques with a diverse set of experimental datasets to provide new insight into the behavior of cancers. The technology allows researchers to peer into the cancer microenvironment to identify the behavior of tumors: the cell phenotypes, how they interact with surrounding tissues, and how they prime their neighbors for invasion, all from the comfort of their computer desk.
Culture Biosciences develops automated bio-reactor that helps biotech companies optimize their manufacturing processes and brings products to market faster. The company also builds automated tools for fermentation. It has a digital bio-manufacturing platform to enable scientists to run, monitor, and analyze bio-reactors faster than traditional approaches by robotic sample handling and cloud data monitoring and analysis. Culture Biosciences was founded in 2016 and is headquartered in San Francisco, California.
Emulate is a privately held company that creates advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health.
Sound Agriculture uses molecular discovery to create climate-resilient crops, enhancing harvest yields for growers. They also use an innovative life science approach to sustainably increase farming productivity. The company was founded in 2013 and headquartered in Emeryville, California.
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics. The company aims to bring simple, elegant, and cost-effective solutions to common problems facing research and development programs.
Torus Biosystems offers an apparatus for DNA testing for scientific and medical research purposes in the fields of consumer products, food for human beings or animals, hygienic and beauty care for human beings or animals, agriculture, horticulture, and forestry. The company was founded in 2019 and is headquartered in Cambridge, Massachusetts.
Isolere Bio is a Healthcare Company.Monoclonal antibodies make up an effective and rapidly growing class of drugs. They are also critical research tools and essential for the development of many new diagnostics. Isolere Bio was co-founded with the vision of simplifying and streamlining the purification of biotherapeutics to improve global access to these important drugs.
Vizgen is a privately held biotech company developing the next generation of spatially resolved, single-cell transcriptomics technology and toolbox. The company's patented MERFISH technology enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and detection efficiency at subcellular resolution.
Scipher Medicine develops a healthcare platform designed to determine which drug will work best for each patient. The company is committed to transforming the way providers prescribe drugs, as well as the way manufacturers, develop new drugs. They are building a molecular map of all protein interactions that identifies genomic signatures and links those to disease and predictive treatment outcomes. Using a simple blood sample to analyze RNA, Scipher Medicine can predict if a patient is likely to respond to a targeted therapy before therapy is prescribed. This insight allows patients to start the most effective therapy from day one. For its first commercial product, they have developed PrismRA®, a first-of-its-kind blood test that can predict which patients with rheumatoid arthritis are less likely to respond to TNFi therapies such as Humira® and Enbrel® so that such patients can go on alternative approved drugs. Scipher Medicine is building the future of patient treatment. Most patients who are prescribed blockbuster therapies today don't respond to treatment, costing the healthcare industry billions in wasted drugs while patients continue to suffer. Scipher's platform identifies which drug will work based on the patient's fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A routine blood test predicts which drug he/she will respond to, with our first product focusing on rheumatoid arthritis, ensuring that the most optimal treatment is prescribed from day one. The molecular data generated by our tests are then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to any existing therapy.
StrideBio is a gene therapy company focused on developing genetic medicines with curative potential for patients with devastating conditions. It leverages its proprietary structure-inspired adeno-associated virus (AAV) vector engineering platform to create unique and differentiated vectors that improve upon naturally occurring AAV serotypes to overcome current limitations of first-generation gene therapies. The company was founded in 2015 and is headquartered in Durham, North Carolina.
Octave is a clinical platform developer who is working to create a new paradigm of multiple sclerosis care by generating, analyzing, and combining data. The platform of the company provides an integrated and multi-dimensional approach to lowering total cost of care by optimizing healthcare medications and utilization, allowing pharma to optimize the entire lifecycle of drug discovery and development, clinical trials, and post-marketing with real-world evidence.
nanoView Diagnostics Inc. (dba NanoView Biosciences), is developing proprietary products that support research, translation and delivery of precision medicine. The Company was founded on a novel technology platform that uniquely identifies and characterizes exosomes. Our high-throughput, cost-effective analysis solutions enable life science researchers to better understand the biological role of exosomes and how to utilize them as biomarkers to provide improved insight for how diseases are diagnosed, treated and monitored.
Emulate is a privately held company that creates advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health.
Vizgen is a privately held biotech company developing the next generation of spatially resolved, single-cell transcriptomics technology and toolbox. The company's patented MERFISH technology enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and detection efficiency at subcellular resolution.
IsoPlexis is a life science technology company developing a single-cell detection system that identifies a wide range of patient immune responses at the single-cell level. Its platform can assess the safety and efficacy of therapeutics and monitor disease progression, enabling improved therapeutic development, and informing physician decisions. The company was founded in 2013 and is headquartered in Branford, Connecticut.
IsoPlexis is a life science technology company developing a single-cell detection system that identifies a wide range of patient immune responses at the single-cell level. Its platform can assess the safety and efficacy of therapeutics and monitor disease progression, enabling improved therapeutic development, and informing physician decisions. The company was founded in 2013 and is headquartered in Branford, Connecticut.
Codex DNA is a biology company helping researchers with the tools they need to securely design, code, and create synthetic DNA. The company is on a mission to help scientific researchers in both academic and commercial settings with the hardware, software, materials, and methodologies required to rapidly and accurately write large quantities of synthetic genes. To, in effect, build biology. Its gene synthesis portfolio reduces the turnaround time for synthesizing workflows from weeks and months to days and hours and includes the BioXp system, DNA services, Gibson Assembly reagents, and Vmax chemically competent cells. In addition to automating, speeding, and optimizing DNA design and synthesis, Codex DNA and the BioXp system ensure your designs stay in your hands, marrying speed and security for innovators in drug discovery, vaccine development, precision medicine, and beyond. Co-founded by Dan Gibson — the creator of the industry-standard Gibson Assembly methodology — Codex DNA is attempting nothing less than changing everything.
Codex DNA is a biology company helping researchers with the tools they need to securely design, code, and create synthetic DNA. The company is on a mission to help scientific researchers in both academic and commercial settings with the hardware, software, materials, and methodologies required to rapidly and accurately write large quantities of synthetic genes. To, in effect, build biology. Its gene synthesis portfolio reduces the turnaround time for synthesizing workflows from weeks and months to days and hours and includes the BioXp system, DNA services, Gibson Assembly reagents, and Vmax chemically competent cells. In addition to automating, speeding, and optimizing DNA design and synthesis, Codex DNA and the BioXp system ensure your designs stay in your hands, marrying speed and security for innovators in drug discovery, vaccine development, precision medicine, and beyond. Co-founded by Dan Gibson — the creator of the industry-standard Gibson Assembly methodology — Codex DNA is attempting nothing less than changing everything.
SeLux Diagnostics is a developer of the next-generation phenotyping platform that provides personalized antimicrobial therapies to patients. The company is revolutionizing patient care by expediting the selection of personalized antimicrobial therapy for all infectious disease patients. This advancement will save lives, reduce hospital stays, and address the escalating antibiotic resistance epidemic by minimizing the overuse of broad-spectrum agents.
IsoPlexis is a life science technology company developing a single-cell detection system that identifies a wide range of patient immune responses at the single-cell level. Its platform can assess the safety and efficacy of therapeutics and monitor disease progression, enabling improved therapeutic development, and informing physician decisions. The company was founded in 2013 and is headquartered in Branford, Connecticut.
Scipher Medicine develops a healthcare platform designed to determine which drug will work best for each patient. The company is committed to transforming the way providers prescribe drugs, as well as the way manufacturers, develop new drugs. They are building a molecular map of all protein interactions that identifies genomic signatures and links those to disease and predictive treatment outcomes. Using a simple blood sample to analyze RNA, Scipher Medicine can predict if a patient is likely to respond to a targeted therapy before therapy is prescribed. This insight allows patients to start the most effective therapy from day one. For its first commercial product, they have developed PrismRA®, a first-of-its-kind blood test that can predict which patients with rheumatoid arthritis are less likely to respond to TNFi therapies such as Humira® and Enbrel® so that such patients can go on alternative approved drugs. Scipher Medicine is building the future of patient treatment. Most patients who are prescribed blockbuster therapies today don't respond to treatment, costing the healthcare industry billions in wasted drugs while patients continue to suffer. Scipher's platform identifies which drug will work based on the patient's fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A routine blood test predicts which drug he/she will respond to, with our first product focusing on rheumatoid arthritis, ensuring that the most optimal treatment is prescribed from day one. The molecular data generated by our tests are then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to any existing therapy.
Sherlock Biosciences is a biotechnology company based in Cambridge, Massachusetts, focused on developing molecular diagnostic solutions. Incorporated in 2018, the company utilizes cutting-edge engineering biology tools, including CRISPR and synthetic biology, to create innovative diagnostic platforms. Its primary products include SHERLOCK, a CRISPR-based method for detecting and quantifying specific genetic sequences, and INSPECTR, a synthetic biology-based diagnostics platform. These technologies aim to provide rapid, accurate, and affordable results across various applications, including precision oncology, infection identification, food safety, at-home testing, and disease detection. By leveraging these advanced tools, Sherlock Biosciences addresses the need for effective diagnostics in both high and low-resource settings.
SeLux Diagnostics is a developer of the next-generation phenotyping platform that provides personalized antimicrobial therapies to patients. The company is revolutionizing patient care by expediting the selection of personalized antimicrobial therapy for all infectious disease patients. This advancement will save lives, reduce hospital stays, and address the escalating antibiotic resistance epidemic by minimizing the overuse of broad-spectrum agents.
nanoView Diagnostics Inc. (dba NanoView Biosciences), is developing proprietary products that support research, translation and delivery of precision medicine. The Company was founded on a novel technology platform that uniquely identifies and characterizes exosomes. Our high-throughput, cost-effective analysis solutions enable life science researchers to better understand the biological role of exosomes and how to utilize them as biomarkers to provide improved insight for how diseases are diagnosed, treated and monitored.
SeLux Diagnostics is a developer of the next-generation phenotyping platform that provides personalized antimicrobial therapies to patients. The company is revolutionizing patient care by expediting the selection of personalized antimicrobial therapy for all infectious disease patients. This advancement will save lives, reduce hospital stays, and address the escalating antibiotic resistance epidemic by minimizing the overuse of broad-spectrum agents.